Click here for slides on this topic


Glucagon-like peptide-1 (GLP-1)

A human incretin hormone that is released from intestinal L cells after the ingestion of carbohydrates and fat. GLP-1 exerts multiple effects to mediate the body's ability to self-regulate blood glucose. The effects include enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, reducing food intake and regulating gastric emptying. Animal studies suggest GLP-1 may have the ability to stimulate beta-cell proliferation and neogenesis.


The following content matched the glossary term: Glucagon-like peptide-1 (GLP-1)

Fonseca commentary on ADVANCE, SOS, VADT

Top

Expert commentary from NDEI Education Council Member Vivian A. Fonseca, MD, on data from post-hoc analyses of ADVANCE, SOS, and VADT.

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Top

Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124. DURATION (Diabetes Therapy Utilization: Researching Changes in A1C, Weight, and Other Factors Through Intervention with Exenatide Once-Weekly) is a series of multinational studies comparing once-weekly exenatide with other antihyperglycemic therapies for treatment of type 2 diabetes.

Clinical Insights in Diabetes Newsletter November 2012

Top

Clinical Insights® in Diabetes Newsletter November 2012.

Statins and diabetes, Roux-en-Y for type 2 diabetes and obesity, sitagliptin or liraglutide for type 2 diabetes treatment, obesity and mortality, and DPP-4 inhibitors and cardiovascular disease.

Efficacy & safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 wks in metformin-treated patients

Top

Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986-1993. In 2011, Pratley and colleagues reported 52-week data from a trial that explored treatment with the DPP-4 inhibitor, sitagliptin, and the GLP-1 receptor agonist, liraglutide, among subjects with type 2 diabetes and A1C 7.5%–10%.

Effects of glucagon-like peptide-1 receptor agonists on weight loss

Top

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj.d7771. Vilsbøll and colleagues conducted a meta-analysis and systematic review of trials to analyze the risks and benefits of GLP-1 receptor agonists among overweight or obese subjects with type 2 diabetes.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults

Top

Tzefos M, Harris K, Brackett A. Clinical efficacy and safety of once weekly glucagon like peptide 1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother. 2012;46(1):68-78. OBJECTIVE: To review pharmacologic, pharmacokinetic, efficacy, and safety data of once-weekly glucagon-like peptide-1 (GLP-1) agonists exenatide long-acting release (LAR), albiglutide, and taspoglutide in treatment of type 2 diabetes mellitus (T2DM).

Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction

Top

Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes. 2011 Oct 17. [Epub ahead of print] AIMS: To evaluate the effects of adding glucagon-like peptide-1 (GLP-1) analogue therapy to insulin on glycated hemoglobin (HbA1c), weight, insulin dosage, treatment satisfaction, and risk of hypoglycaemia.

Efficacy & Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared w/ Exenatide Twice Daily & Sitagliptin in Type 2 Diabetes Mellitus

Top

Pinelli NR, Hurren KM. Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis (July/August). Ann Pharmacother. 2011 Jul 5. [Epub ahead of print]. Long-acting glucagon-like peptide-1 receptor agonists (LA-GLP-1RAs) may deliver additional therapeutic benefits over other available incretin-based therapies.

Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists

Top

Hansen KB, Knop FK, Holst JJ, Vilsbøll T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int J Clin Pract. 2009;63(8):1154-1160. The incretin system is an area of great interest for the development of new therapies for the management of type 2 diabetes. Existing antidiabetic drugs are often insufficient at getting patients to glycaemic goals.

Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes

Top

Al Omar MA, Al Arifi MN. Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes. Saudi Med J. 2005;26:1511-1515. Glucagon-like peptide GLP-1 is an endogenous insulinotropic/glucagonostatic hormone that acts in a self-limiting mechanism.



Slide Library Results

Search Results for: Glucagon-like peptide-1 (GLP-1) Slides Found: 29
Glucagon-Like Peptide-1
Insulin and GLP-1 Responses to Meals
GLP-1 Release Is Reduced in Type 2 Diabetes
Effect of GLP-1 on the Beta-Cell
GLP-1 Infusion Improves Beta-Cell Insulin Secretion
GLP-1 and First-Phase Insulin Secretion
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: A1C
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: Body Weight
Once-Weekly Exenatide LAR vs Twice-Daily Exenatide for Type 2 Diabetes: A1C Categories
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Design
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Results
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Additional Results
DURATION-6: Design
LEAD-3: Liraglutide vs Glimepiride: A1C Level
LEAD-3: Liraglutide vs Glimepiride in Drug-Naïve Patients: A1C
LEAD-3: Liraglutide vs Glimepiride in Previously on Oral Agents: A1
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI